Month: August 2021

BOUSSARD & GAVAUDAN HOLDING LIMITEDRegistration Number: 45582 Registered Office: Ground Floor, Dorey Court, Admiral Park, St Peter Port, Guernsey, GY1 2HTTel: +44 (0)1481 702 400 Fax: +44 (0)1481 702 407 NOTICE OF ANNUAL GENERAL MEETING NOTICE IS HEREBY GIVEN that the Annual General Meeting (the “AGM”) of the Company will be held at Ground Floor, Dorey Court, Admiral Park, St. Peter Port, Guernsey on Thursday, 23 September 2021 at 10:00 a.m. for the purpose of considering and, if thought fit, passing the following resolutions:Ordinary Business – Ordinary Resolutions1. THAT the Company’s annual report and audited financial statements for the year ended 31 December 2020 be received and adopted.2. THAT Ernst & Young LLP be re-appointed as auditor of the Company, to hold such office until the conclusion of the next...

Please find attached the circularAttachment1. BGHL – AGM Circular final version v5 -Final version

BOUSSARD & GAVAUDAN HOLDING LIMITEDRegistration Number: 45582 Registered Office: Ground Floor, Dorey Court, Admiral Park, St Peter Port, Guernsey, GY1 2HTTel: +44 (0)1481 702 400 Fax: +44 (0)1481 702 407 NOTICE OF ANNUAL GENERAL MEETING NOTICE IS HEREBY GIVEN that the Annual General Meeting (the “AGM”) of the Company will be held at Ground Floor, Dorey Court, Admiral Park, St. Peter Port, Guernsey on Thursday, 23 September 2021 at 10:00 a.m. for the purpose of considering and, if thought fit, passing the following resolutions:Ordinary Business – Ordinary Resolutions1. THAT the Company’s annual report and audited financial statements for the year ended 31 December 2020 be received and adopted.2. THAT Ernst & Young LLP be re-appointed as auditor of the Company, to hold such office until the conclusion of the next...

Basel, 27 August 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the company has made the decision to voluntarily withdraw the US accelerated approval for Tecentriq® (atezolizumab) in combination with chemotherapy (Abraxane®, albumin-bound paclitaxel; nab-paclitaxel) for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) whose tumours express PD-L1, as determined by a US Food and Drug Administration (FDA)-approved test. Roche made this decision following consultation with the US FDA, based on the agency’s assessment of the current mTNBC treatment landscape and in accordance with the requirements of the accelerated approval programme. This decision only impacts the mTNBC indication in the US. It does not affect other approved indications for Tecentriq in the...

PRESS RELEASEParis, 27 August 2021 (5:45pm) ADLPartner / ADLPerformance2021 FIRST-HALF NET SALES: €75.5M (+16.4%)STRONG GROWTH IN DIGITAL MARKETING: €30.9M (+40.7%) Following robust sales growth during the first quarter of 2021, the ADLPerformance Group ramped up its growth during the second quarter of 2021, with net sales1 of €37.7m, up +29.1% versus the second quarter of 2020 and +12.9% compared with the second quarter of 2019 before the health crisis. For the first half of 2021, the ADLPerformance Group is reporting consolidated net sales of €75.5m, up +16.4% versus the first half of 2020 and +12.9% versus the first half of 2019. The gross sales volume2 came to €151.2m, up +10.7% compared with the first half of 2020. The Group’s gross margin3 climbed +12.0% to €63.9m. The Digital Marketing business is capitalizing on the strong commercial...

TORONTO, Aug. 27, 2021 (GLOBE NEWSWIRE) — Abaxx Technologies Inc. (NEO:ABXX) (OTCQX:ABXXF) (“Abaxx” or the “Company”), a financial software (fintech) company, majority shareholder of Abaxx Singapore Pte. Ltd. the Abaxx Commodity Exchange (ACX), and producer of the SmarterMarkets™ Podcast, is pleased to announce the results of its annual and special meeting of shareholders held in Toronto on August 25, 2021 (the “Meeting”). A total of 30,514,174 common shares, representing 42.96% of the issued and outstanding common shares of the Company, were represented at the meeting. Seven (7) directors were elected to the Company for the ensuing year. The following is a tabulation of the votes submitted by management proxy:Director Nominee Votes in Favour % Votes Withheld %Joshua Crumb 11,926,984 94.95% 634,567 5.05%Thom McMahon 12,542,325 99.85% 19,226 0.15%Margot...